Table 3.
Per-patient, per-year of treatment by TKI estimated from a cohort of patients with chronic myeloid leukemia observed in Truven’s MarketScan claims database (2011–2012; 2013 $USD) for model health states
| Total annual costs after generic entry of imatinib* | Base case (range for sensitivity analyses) |
|---|---|
| 12-month complete cytogenetic response | |
| Imatinib 1 y | 79 373 (65 415–87 748) |
| Imatinib 2–4 y | 45 875 (37 500–54 249) |
| Dasatinib | 92 117 (78 300–105 935) |
| Nilotinib | 87 445 (74 328–100 562) |
| 3-month BCR/ABL1 early molecular response | |
| Imatinib 1–3 mo | 21 937 (18 646–25 228) |
| Dasatinib 1–3 mo | 23 029 (19 575–26 484) |
| Nilotinib 1-3mo | 21 861 (18 582–25 141) |
| Imatinib 4–12 mo | 57 436 (48 821–66 052) |
| Dasatinib 4–12 mo | 69 088 (58 725–79 451) |
| Nilotinib 4–12 mo | 65 584 (55 746–75 422) |
| Imatinib 2–4 y | 45 875 (38 993–52 756) |
| Dasatinib 2–4 y | 92 117 (78 300–105 935) |
| Nilotinib 2–4 y | 87 445 (74 328–100 562) |
| Allogeneic transplant | 245 000 (125 000–300 000) |
* These cost data represent the mean payer prices of drugs, rather than the list price, to accurately represent the US commercial payer perspective. All predicted cost data are based on trends according to Conti and Berndt (2014) and crosschecked with other published estimates of generic prices of oral drugs. Cost of allogeneic transplantation was drawn from Preussler (2012). All other costs are based on cases billed according to ICD-9; see text for a list of ICD-9 codes. Total costs are the sum of direct expenditures for chronic myeloid leukemia. TKI = tyrosine kinase inhibitor.